Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance.

نویسندگان

  • F J Boswell
  • J M Andrews
  • G Jevons
  • R Wise
چکیده

In this study the in vitro activities and pharmacodynamic properties of moxifloxacin, levofloxacin, gatifloxacin and gemifloxacin were compared on recently isolated respiratory pathogens and strains of Streptococcus pneumoniae with known mechanisms of fluoroquinolone resistance. In addition, the resistance selection frequencies of moxifloxacin and levofloxacin on three recently isolated respiratory pathogens and four strains of S. pneumoniae with known mechanisms of fluoroquinolone resistance were investigated. The four fluoroquinolones had similar activities against both Moraxella catarrhalis (MIC(90)s 0.015-0.06 mg/L) and Haemophilus influenzae (MIC(90)s 0.008-0.03 mg/L). More marked differences in activity were noted with S. pneumoniae, with MIC(90)s of 0.25, 1, 0.5 and 0.03 mg/L for moxifloxacin, levofloxacin, gatifloxacin and gemifloxacin, respectively. With the S. pneumoniae strains, the four fluoroquinolones exhibited similar concentration-dependent time-kill kinetics. The resistance selection frequencies of levofloxacin were higher than those of moxifloxacin at concentrations equivalent to those at the end of the dosing interval. Therefore moxifloxacin may have less of an impact on the development of resistance than levofloxacin.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Detection of Efflux Pumps Genes in Fluoroquinolones Resistant and Sensitive strains of Escherichia coli isolated from Patients with Urinary Tract Infection in Qom

Abstract Background and Objectives: Efflux pumps are one of the main mechanisms for antibiotic resistance in Escherichia coli strains. The aim of this study was to investigate the relationship between 5 different efflux pump genes; acrA, acrB, emrA, emrB and mdtk and fluoroquinolone resistance in E.coli Isolated from patients with urinary tract infections in Qom. Methods: In this descriptive cr...

متن کامل

DRUG PROFILE Management of community-acquired lower respiratory tract infections: gemifloxacin, a new economic paradigm

10.2217/14750708.2.3.357 © 2 part of Lower respiratory tract infections account for over 50 million deaths each year globally. They exert a growing clinical and financial burden on healthcare systems and employers. The increasing prevalence of antimicrobial resistance among usual bacterial pathogens over the past 10 years further drives this burden of disease. Typically, species such as Strepto...

متن کامل

Newer fluoroquinolones and the management of respiratory tract infections.

Infections of the respiratory tract remain one of the leading causes of death in the United States [1]. The cost burden for bacterial infections of the upper and lower respiratory tract is tremendous; the cost alone of treating patients with communityacquired pneumonia (CAP) has recently been estimated to be close to $10 billion (US) [2]. In addition, the emergence of drugresistant pathogens pr...

متن کامل

Antibacterial activity of Tribulus terrestris and its synergistic effect with Capsella bursa-pastoris and Glycyrrhiza glabra against oral pathogens: an in-vitro study

Objective: In this study, antimicrobial activities of an ethanol extract of Tribulus terrestris aloneand in combination with Capsella bursa-pastoris and Glycyrrhiza glabra were examined in vitro against six pathogens namely Streptococcus mutans, Streptococcus sanguis, Actinomyces viscosus, Enterococcus faecalis Staphylococcus aureus, and Escherichia coli. Materials and methods: Antibacterial ac...

متن کامل

Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.

Ciprofloxacin, the first fluoroquinolone to be used to treat lower respiratory tract infections (LRTI), demonstrates poor potency against Streptococcus pneumoniae, and its use has been associated with the emergence of resistance. During the last decade, fluoroquinolones with enhanced in vitro activity against S. pneumoniae have replaced ciprofloxacin for the treatment of LRTI. Here, we analyzed...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • The Journal of antimicrobial chemotherapy

دوره 50 4  شماره 

صفحات  -

تاریخ انتشار 2002